- Home
- FTDR vs SRRK Comparison
FTDR vs SRRK Comparison
Compare FTDR & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | SRRK |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.6B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FTDR | SRRK |
|---|---|---|
| Price | $56.61 | $42.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $59.75 | $47.88 |
| AVG Volume (30 Days) | 659.8K | ★ 1.7M |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | ★ 3.46 | N/A |
| Revenue | ★ $2,042,000,000.00 | N/A |
| Revenue This Year | $15.25 | N/A |
| Revenue Next Year | $5.74 | $20,271.77 |
| P/E Ratio | $16.09 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $35.61 | $22.71 |
| 52 Week High | $70.14 | $48.28 |
Technical Indicators
Market Signals| Indicator | FTDR | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 55.29 |
| Support Level | $55.20 | $42.61 |
| Resistance Level | $56.60 | $45.32 |
| Average True Range (ATR) | 1.38 | 2.24 |
| MACD | 0.78 | -0.46 |
| Stochastic Oscillator | 98.73 | 39.11 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.